Multiple sclerosis belongs to the prevailing neurological disorders affecting young and middle-aged people. There are about 2 million people suffering from multiple sclerosis worldwide. The disease usually occurs at the age of thirty and more often affects females. Most often multiple sclerosis develops in Caucasians living in the moderate climate. This disease ranks number three among the most debilitating illnesses after injuries and rheumatologic diseases in the reproductive period.

Multiple sclerosis is a chronic neurological disease with unpredictable and often progressive course. In multiple sclerosis, the brain, spinal cord, optic nerves are damaged resulting in the impairment of the body functions.

The underlying mechanism of the disease is destruction of the myelin, or white fatty matter covering the nerve fibers (axons) and having electroinsulating function. This process is called demyelination. Demyelination is considered to occur as a body response to its own myelin. The foci of demyelination in the brain and spinal cord are called plaques. Their size can vary from several millimeters to several centimeters; the plaques can merge into the bigger ones.

Damage of myelin leads to impairment of nervous impulses conduction between the brain and organs, thus, determining the disease manifestations. At the early stages, when a patient already has the foci of multiple sclerosis in the brain, neurological symptoms of the disease can be hidden. The healthy nervous fibers compensate the function of the damaged ones unless their number reaches 40-50%, and only afterwards the focal neurological symptoms appear.

The causes of multiple sclerosis have not been defined yet. Although multiple sclerosis is believed to be an autoimmune disease, it is unclear whether these reactions are primary or secondary. If inflammation and demyelination in the brain tissue is caused by autoimmune attack against the brain cells, it is possible to suggest the primary nature of the autoimmune process.

Multiple sclerosis is not a hereditary disease. No specific gene is responsible for the MS development. A certain combination of genes may predispose to multiple sclerosis, but such combination of genes can be also found in healthy people. There is only a 2% probability that a child will develop this disease is the parents are affected with MS to.

The farther from the equator, the more likely MS is to occur. The risk factors for the development of MS may be infections and viruses. Though no specific virus triggering the autoimmune processes in multiple sclerosis has been defined, some investigators believe that typical virus infections in childhood can be triggering factors for MS development.

About 40% of multiple sclerosis sufferers demonstrate motor disturbances, for example, muscle weakness, and difficulties with coordination. MS patients can also develop central and peripheral paralysis of cranial nerves, most often – of oculomotor nerves, trigeminal, facial and hypoglossal nerves. MS patients can also suffer from sensitivity disturbances, such as numbness or tingling in the extremities. Visual problems, for example, decrement in visual acuity of one or both eyes, visual field defect, unclear vision, loss of light perception, colour distortion and contrast disturbances are observed in 20% of MS cases. Typically, MS sufferers complain of walking disturbances, easy tiredness, sexual dysfunction and uncontrolled urination. Neuropsychological changes in MS patients include cognitive impairment, behavioral disorder and lack of emotional control.

Multiple sclerosis treatment with stem cells

Multiple sclerosis treatment with fetal stem cells results in the pronounced positive effect in all cases. The most successful results of the therapy are reported in patients with relapsing-remitting multiple sclerosis (successful rate up to 90%) but in other types of multiple sclerosis patients also report improvement of their condition (successful rate up to 59%).

The goal of multiple sclerosis treatment is to interrupt the immune aggression against patient’s own nervous system in order to eliminate the main mechanism of disease development. Fetal stem cell transplantation stops disease progression and leads to regression of the neurological symptoms. No relapses were reported during the follow-up period (up to 5 years after the treatment).

Effects of multiple sclerosis treatment with fetal stem cells

Stem cell treatment of multiple sclerosis leads to rapid improvement of patient’s psycho-emotional condition, while neurological effects develop within a long period of time. Most patients (93%) showed syndrome of early posttransplantation improvements. The syndrome manifests in the decrease of weakness, appearance of vivacity, improvement of appetite and mood. Moreover, a part of patients (63% cases) report deeper psychosomatic changes, such as decreased depression, phobias, anxiety about the future, more confidence in their recovery, better work capacity, improved ability to concentrate their attention (this leads, for example, to better results of professional and training activities).

Within a year after the treatment, many multiple sclerosis patients report restoration of the eyesight, improvement of the mental capacity and emotional sphere, disappearance of depression. Such disorders as motor and speech disturbances, disturbances of the gastrointestinal tract and dysfunction of the pelvic organs also retreat but require more time, and such patients need to repeat the multiple sclerosis treatment (about 72%).

Patients with primary progressive multiple sclerosis report stop of the disease progression in 3–6 months after the fetal stem cell transplantation.

Restoration of the nervous system is a prolonged process and requires patience. Over the first year of stem cell therapy, patients should undergo 1 to 3 treatment courses and one more treatment course in 1–2 years to maintain the achieved results. The course of multiple sclerosis treatment at the EmCell Clinic, as a rule, lasts for 2 days.

Results of fetal stem cell treatment of multiple sclerosis

Subtypes of multiple sclerosis
Treatment of patients with remitting-relapsing multiple sclerosis
Treatment of patients with secondary progressive multiple sclerosis
Treatment of patients with primary progressive multiple sclerosis
Dynamics of neurological symptoms in 18 multiple sclerosis cases after the stem cell therapy

Medical case reports

The first course of multiple sclerosis treatment in patient D.C.
The second course of multiple sclerosis treatment in patient D.C.
The third course of multiple sclerosis treatment in patient D.C.

Patients' feedbacks

The patient's H. feedback after the second course of stem cell treatment
The feedback of the patient V.A. after the course of stem cell treatment of multiple sclerosis

Comments

Name
E-mail

Enter
the number